Part of The Mesothelioma Center. Contact Us
Mesothelioma-Line.com.
Journal Articles on Mesothelioma: Cancer Information for Patients and Families

Archive for the 'Surgery' Category

Surgery or surgeries used in the treatment of malignant mesothelioma.

Surgery news feed.

December 25th, 2008. Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy

Conclusion: Cytoreductive surgery combined with HIPEC may improve the length of survival for patients with diffuse malignant peritoneal mesothelioma; such patients should be treated in specialized centers.

December 20th, 2008. Vitamin D-mediated hypercalcemia and Cushing syndrome as manifestations of malignant pleural mesothelioma

Conclusion: These findings support the evidence for a paracrine role of vitamin D in the resistance of the human host to antigen.

December 17th, 2008. Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

We conclude that minimal residual disease, compared with macroscopically complete cytoreduction, correlated to failure in critical anatomical areas, suggesting the need for maximal cytoreductive surgical efforts. In selected patients, aggressive management of progressive disease seems worthwhile.

December 4th, 2008. Cytoreductive surgery and continuous hyperthermic peritoneal perfusion in patients with mesothelioma and peritoneal carcinomatosis: hemodynamic, metabolic, and anesthetic considerations

0082) after completion of CHPP compared with patients with peritoneal carcinomatosis. We conclude that the transient hemodynamic and metabolic perturbations associated with cytoreductive surgery and CHPP with cisplatin can vary according to the primary diagnosis (mesothelioma versus peritoneal carcinomatosis) warranting this therapy.

November 26th, 2008. Mesothelioma: treatment

There are few active cytotoxic drugs in this disease. Currently, based on two randomised trials, the most efficacious chemotherapy regimen consists in a combination of cisplatin and an antifolate agent, pemetrexed or raltitrexed.

November 21st, 2008. Compensator-based intensity-modulated radiation therapy for malignant pleural mesothelioma post extrapleural pneumonectomy

Not all linear accelerators can deliver large-field MLC-based IMRT, but most can deliver a maximum conformal field of 40 x 40 cm. It is possible and reasonable to deliver IMRT with compensators for fields this size with most conventional linear accelerators.

November 20th, 2008. Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y. Department of Oncology, Zhongnan Hospital, Cancer Center of Wuhan University, Hubei Cancer Clinical Study Center, Wuchang District, China.

Eleven patients died, three survived with tumor, and seven survived free of tumor. CRS + HIPEC was well tolerated in our selected patients with PC, some of whom had improved survival.

November 17th, 2008. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience

Conclusion: CRS and HIPEC is a treatment option for peritoneal mesothelioma. Patients with epithelioid tumor who undergo complete cytoreduction may potentially benefit from this procedure.

November 11th, 2008. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma

With longer follow-up, mut+ may not only be predictive of survival but may represent a subset of patients whose disease may be responsive to TK-inhibitor therapy. Experiments confirming the activating properties of the novel mutations are warranted.

November 6th, 2008. Benign mesothelioma of peritoneum presenting as a pelvic mass

Postoperative recovery was satisfactory. At 3 years follow-up, patient is symptom-free.

November 5th, 2008. Malignant mesothelioma of the tunica vaginalis: a case report

The patient has not received additional therapy because there has been no evidence of metastasis. He has been free of disease 3 months postoperatively.

November 5th, 2008. Case of malignant mesothelioma presenting as a perineal and intrascrotal mass

The patient died six months after the initiation of therapy. To our knowledge, 24 cases of malignant mesothelioma in the perineum or intrascrotum were reported in Japan and this case was thought to be the 25th case in Japan.

November 5th, 2008. Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma

Conclusions: Cytoreductive surgery combined with intraperitoneal chemotherapy appears to be the optimal treatment for selected patients with peritoneal mesothelioma. Increased familiarity with this condition's presentation and natural history, and knowledge of available treatment options, will hopefully facilitate treatment of these patients and expedite speedy referral to appropriate treatment centres.

November 5th, 2008. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study

Conclusion: The treatment yields good results with a high number of responses and long survival, and a low toxicity. The long survival of the epitheloid subgroup with good prognostic factors is as good as or even better than some studies on radical surgery or multimodal treatment, underlining the need of randomized studies to evaluate such treatment options.

October 31st, 2008. Diffuse malignant pleural mesothelioma: A multi-institutional clinicopathological study

Conclusions: The definitive diagnosis of early MPM is difficult, but establishing the best diagnostic modality would improve survival rates, since radical surgery is likely to be effective for resectable disease.

October 23rd, 2008. Malignant abdominal mesothelioma: defining the role of surgery

Conclusion: Surgical extirpation of MAM may be associated with significantly improved survival. All patients with MAM should be evaluated for potential surgical resection.

October 22nd, 2008. A case of non-tuberculous mycobacteriosis with pleurisy with a past history of dense exposure to environmental asbestos

A final diagnosis of NTM was confirmed via open biopsy of the lung. Our case suggests that in addition to tuberculosis, NTM should be taken into consideration as a complication of silicosis.

October 22nd, 2008. A case of solid pseudopapillary tumour of the pancreas and malignant mesothelioma

Discussion: An abdominal computerised tomogram revealed pancreatic body mass arising. Pleural fluid cytology and a pleural biopsy failed to demonstrate malignancy. The pancreatic tumour was resected by distal pancreatectomy, segmental colectomy and splenectomy. The tumour was a solid pseudopapillary pancreatic tumour (SPT) with a high metastatic potential. The patient deteriorated and a repeat biopsy of the thickened pleura confirmed malignancy which was initially thought to be metastases from the SPT. Immunohistochemical staining confirmed malignant mesothelioma. The patient developed liver metastases and died 2 years from the diagnosis of metastatic disease.

October 16th, 2008. Histologic assessment and prognostic factors of malignant pleural mesothelioma treated with extrapleural pneumonectomy

Postoperative treatment was associated with DSS and with recurrence-free survival. Our study confirms that in many cases, final histopathologic typing of MPM is influenced by complete surgical resection and that initial biopsy should be carefully weighed in the treatment stratification.

October 9th, 2008. Peritoneal Mesothelioma

To date there have been no universally accepted treatments for MPM. Unless referred to a specialty center, patients are routinely treated with pemetrexed and cisplatin which has been shown to increase survival in pleural mesothelioma.